Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05663853 · ClinicalTrials.gov registry record
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
A clinical trial, sponsored by LAPIX Therapeutics.
- Completed
- Registry status
- 137
- Enrollment target
NCT05663853 is a clinical trial that has completed, run by LAPIX Therapeutics. The registered enrollment target is 137 participants.
The verdict
NCT05663853 has completed, sponsored by LAPIX Therapeutics.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
Study Summary
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to participate in this Observational study being conducted across four sites in the US. Since this is an observational study no medication/drug or treatment will be given to the participants. The investigator will be collecting information about the participant's MS disease, its progression, current medications, radiographic scans, and blood samples. This will help the investigator evaluate the biomarkers and new treatment options to better understand the MS disease process.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2024-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05663853
The ClinicalTrials.gov registry entry for NCT05663853 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LAPIX Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05663853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05663853 about?
NCT05663853 is a clinical study titled "An Observational Biomarker Study in Multiple Sclerosis (MS) Patients". All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to participate in this Obs...
What is the current status of trial NCT05663853?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2023-03-28. Estimated completion is 2024-04-30.
Who is sponsoring clinical trial NCT05663853?
This trial is sponsored by LAPIX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.